|
This is up from an original $500 million target set by the fund,
which is investing in mid- to late-stage companies in digital
health, medical devices and biopharma in Israel, the United
States and Europe.
Launched in 2018, aMoon II said in May it had secured a $250
million investment commitment from Credit Suisse's asset
management and private banking divisions.
The fund intends to invest $10 million to $40 million in 15 to
20 companies over the next five years.
aMoon was founded in 2016 by Marius Nacht, co-founder and
chairman of Check Point Software Technologies, and Yair Schindel.
Their first fund, the $200 million aMoon I, invested in 20
startups.
A third fund, aMoon Velocity, which will focus on early-stage
startups, is open only to investors in aMoon II and has a
fundraising target of $120 million.
Nacht is investing $360 million of his own money in the three
funds, according to the document.
Company officials on Wednesday declined to comment.
Israel has about 1,500 life science companies, a number expected
to reach 2,500 in the next five years as the government provides
tax breaks and other financial incentives.
Israel also has two of the largest healthcare databases in the
world and multinationals such as Novartis, Johnson & Johnson and
Merck Serono operate research centers there.
aMoon II has invested in four companies, including $10.6 million
in cancer therapy firm Ayala Pharmaceuticals, in which
Bristol-Myers Squibb co-invested. aMoon's investment was worth
$145 million according to Ayala's last fundraising round.
(Reporting by Tova Cohen; Editing by Steven Scheer and Alexandra
Hudson)
[© 2019 Thomson Reuters. All rights
reserved.] Copyright 2019 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
 |
|
